Welcome to our dedicated page for KESTRA MED TECHNOLOGIES SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) provides access to the company’s official regulatory documents as a Bermuda-incorporated, Nasdaq-listed wearable medical device and digital healthcare company. These filings offer structured insight into Kestra’s financial condition, governance, and key events related to its Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator.
Users can review current reports on Form 8-K, where Kestra discloses material information such as quarterly financial results, preliminary performance updates, and significant clinical communications. For example, the company has used Form 8-K to furnish press releases on fiscal quarter results and to report the announcement of ACE-PAS study findings presented at a major cardiology meeting.
Kestra’s proxy materials on Schedule 14A (DEF 14A) describe matters submitted to shareholders, including the election of directors, ratification of the independent registered public accounting firm, and approval of an employee stock purchase plan. These documents also reference the presentation of audited financial statements contained in the company’s Annual Report on Form 10-K.
Over time, investors can also reference annual reports (Form 10-K) and quarterly reports (Form 10-Q), which provide more detailed discussions of Kestra’s business, risk factors, financial statements, and management’s analysis of results. These filings are important for understanding how Kestra reports on commercialization of its wearable defibrillator platform, research and development spending, and broader corporate activities.
On Stock Titan, Kestra’s filings are updated as they are made available through EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlight notable changes from prior periods, and surface items such as financial performance metrics, governance decisions, and major clinical or commercial disclosures. Users can quickly move from high-level summaries to full-text filings for deeper review.
Kestra Medical Technologies, Ltd. filed an automatic shelf registration on April 1, 2026 to offer and sell common shares from time to time under Form S-3 as a well‑known seasoned issuer. The prospectus permits offerings in amounts, at prices and on terms to be determined in each prospectus supplement, with sales commencing from time to time after the registration statement is declared effective.
The prospectus describes the company’s Cardiac Recovery System and its ASSURE WCD wearable defibrillator — which has been worn by over 33,000 patients as of January 2026 — and provides customary risk factors, tax discussions (Bermuda, Irish, and U.S. federal), plan of distribution options, and corporate governance and capital structure details. The prospectus discloses Nasdaq listing under the symbol KMTS and a last reported closing price of $19.93 per share on March 31, 2026.
Kestra Medical Technologies director Raymond W. Cohen bought 10,000 Common Shares of KMTS in an open-market purchase at a weighted average price of $19.98 per share. After this transaction, he directly owns 50,903 Common Shares. The footnote explains the trade prices ranged from $19.82 to $20.02 per share.
KESTRA MEDICAL TECHNOLOGIES, LTD. director and officer Brian Daniel Webster reported an open-market sale of 15,000 Common Shares on March 17, 2026 at a weighted average price of $20.2749 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following this sale, Webster continues to hold 364,786 Common Shares directly, showing he retains a substantial equity stake in the company.
Kestra Medical Technologies reported Form 144 notice showing affiliate sales. Brian Webster reported selling common shares in three transactions: 12/29/2025 ($398,847.04), 01/15/2026 ($342,023.69), and 02/17/2026 ($384,020.06), each for 15,000 common shares. The filing also records a restricted share issuance of 15,000 shares on 01/21/2026 granted under the issuer's equity compensation plan.
Kestra Medical Technologies reported strong top-line growth but wider losses as it scales its cardiac recovery platform. Revenue for the quarter ended January 31, 2026 rose to $24.6 million from $15.1 million, with gross profit nearly doubling to $12.9 million.
Nine‑month revenue increased to $66.5 million from $42.6 million, but higher research and development and especially selling, general and administrative expenses drove a quarterly net loss of $34.2 million and a nine‑month net loss of $92.8 million. Cash and cash equivalents were $291.3 million, supported by IPO proceeds and a December 2025 equity offering of 6.9 million shares that raised $149.3 million net. The company believes this liquidity will fund operations and capital needs for at least 12 months, while noting it may pursue additional financing to support growth.
Kestra Medical Technologies reported strong growth for its third fiscal quarter ended January 31, 2026. Revenue reached $24.6 million, up 63% from the prior-year period, driven by higher ASSURE system prescriptions, market share gains and a richer mix of in-network patients.
Gross margin improved to 52.6% from 43.4%, but GAAP net loss widened to $34.2 million from $21.8 million as operating expenses rose with commercial expansion and public company costs. Adjusted EBITDA loss was $21.2 million. Cash and cash equivalents were $291 million as of January 31, 2026, reflecting proceeds from a 6.9 million-share equity offering. The company raised its fiscal 2026 revenue guidance to $93 million, implying 55% growth versus fiscal 2025.
Reilly Kevin C reported acquisition or exercise transactions in this Form 4 filing.
Kestra Medical Technologies director Kevin C. Reilly received an equity award of 8,300 common shares in the form of restricted stock units. The RSUs were granted at no cash cost and each unit represents one common share. All 8,300 RSUs will vest on September 4, 2026, if he continues serving through that date, at which point he would hold 8,300 vested common shares from this award.
Kestra Medical Technologies director and officer Brian Daniel Webster sold a total of 15,000 Common Shares of KMTS in open-market transactions on February 17, 2026. The sales occurred under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025.
The transactions were executed in three tranches: 11,635 shares at a weighted average price of $25.3937, 3,272 shares at $26.2947, and 93 shares at $27.1789. After these sales, Webster directly held 379,786 Common Shares.
Bain Charger Holdings, L.P., an affiliate of Bain Capital, reports a significant ownership position in Kestra Medical Technologies, Ltd. common shares. As of the close of business on December 31, 2025, Bain Charger directly held 25,172,338 common shares.
These holdings represent approximately 43.1% of Kestra’s outstanding common shares, based on 58,349,053 shares outstanding as of December 5, 2025, as cited from Kestra’s Form 10-Q. Bain Charger and its general partner share voting and dispositive power over these shares.
Kestra Medical Technologies shareholder Brian Webster has filed a Form 144 notice to sell 15,000 common shares. The proposed sale is through Merrill Lynch on NASDAQ, with an aggregate market value of $384,020.06, and an approximate sale date of February 17, 2026.
The 15,000 shares were acquired on March 7, 2025 via a restricted share issuance granted under the issuer’s equity compensation plan. Over the past three months, Webster sold 15,000 common shares on December 29, 2025 for $398,847.04 and another 15,000 shares on January 15, 2026 for $342,023.69.